Drug Profile
Research programme: angiogenesis inhibitors - Medexis
Alternative Names: Angiomed Project; MED-A300; MED-A301Latest Information Update: 10 Dec 2010
Price :
$50
*
At a glance
- Originator Medexis
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Sep 2004 Compounds from this research programme are available for licensing (http://www.medexis-biotech.com)
- 06 Aug 2004 Preclinical trials in Cancer in Greece (unspecified route)